Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-05 00:05 | 2026-03-02 | VCEL | Vericel Corp | Flynn Sean C. | Officer; Chief Legal Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $35.18 | 21,421 | $753,531 | 1,262 | -94.4% |
| 2025-02-27 00:05 | 2025-02-25 | VCEL | Vericel Corp | Flynn Sean C. | Officer; Chief Legal Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $52.07 | 1,669 | $86,905 | 756 | -68.8% |
| 2025-02-25 00:05 | 2025-02-20 | VCEL | Vericel Corp | Flynn Sean C. | Officer; Chief Legal Officer | Biological Products, (No Diagnostic Substances) | SALE | $57.32 | 3,835 | $219,822 | 756 | -83.5% |
| 2024-07-18 23:05 | 2024-07-16 | VCEL | Vericel Corp | Flynn Sean C. | Officer; Chief Legal Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $52.18 | 15,000 | $782,700 | 707 | -95.5% |
| 2024-06-25 01:21 | 2024-06-20 | VCEL | Vericel Corp | Flynn Sean C. | Officer; Chief Legal Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $45.11 | 15,000 | $676,644 | 487 | -96.9% |
| 2024-03-11 23:07 | 2024-03-08 | VCEL | Vericel Corp | Flynn Sean C. | Officer; SVP, General Counsel | Biological Products, (No Diagnostic Substances) | SALE | $45.33 | 8,115 | $367,853 | 167 | -98.0% |
| 2023-12-16 00:07 | 2023-12-13 | VCEL | Vericel Corp | Flynn Sean C. | Officer; SVP, General Counsel | Biological Products, (No Diagnostic Substances) | SALE | $34.42 | 1,538 | $52,944 | 4,467 | -25.6% |
| 2021-08-31 23:10 | 2021-08-27 | VCEL | Vericel Corp | Flynn Sean C. | Officer; VP, General Counsel | Biological Products, (No Diagnostic Substances) | OPT+S | $55.11 | 7,200 | $396,760 | 2,419 | -74.9% |
| 2021-07-23 23:04 | 2021-07-21 | VCEL | Vericel Corp | Flynn Sean C. | Officer; VP, General Counsel | Biological Products, (No Diagnostic Substances) | OPT+S | $55.01 | 2,800 | $154,028 | 2,419 | -53.7% |
| 2021-07-16 23:07 | 2021-07-15 | VCEL | Vericel Corp | Flynn Sean C. | Officer; VP, General Counsel | Biological Products, (No Diagnostic Substances) | OPT+S | $51.18 | 10,000 | $511,786 | 2,419 | -80.5% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.